Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

CAP TODAY

SeraCare launches TMB reference materials

February 2020—SeraCare Life Sciences launched genomic DNA and formalin-fixed, paraffin-embedded reference materials for tumor mutational burden measurement by next-generation sequencing assays. SeraCare collaborated with Friends of Cancer Research and International Quality Network for Pathology in the development and evaluation of a range of gDNA and FFPE-based TMB reference materials across different targeted NGS panels, sequencing platforms, and bioinformatics analysis pipelines.

FDA clears Simplexa VZV Swab Direct

February 2020—DiaSorin Molecular has received FDA clearance for its Simplexa VZV Swab Direct assay. The CLIA moderate-complexity assay is designed for use on the Liaison MDX instrument to detect varicella-zoster virus DNA from cutaneous and mucocutaneous swab specimens. The assay complements the company’s Simplexa VZV Direct kit, which is for use with cerebrospinal fluid samples.

Applied BioCode panel gets FDA clearance

February 2020—Applied BioCode has received FDA 510(k) clearance for its BioCode Respiratory Pathogen Panel for use on the company’s BioCode MDx-3000 system. The panel tests nasopharyngeal swabs for common viruses and bacteria, including influenza A and subtypes H1, H1N1 2009pdm, and H3; influenza B; respiratory syncytial virus A/B; parainfluenza virus types 1–4; human metapneumovirus A/B; adenovirus; rhinovirus/enterovirus; coronavirus (229E, NL63, OC43, and HKU1); Mycoplasma pneumoniae; Chlamydia pneumoniae; and Bordetella pertussis.

FDA approves first vaccine for Ebola virus

February 2020—The U.S. Food and Drug Administration announced the approval of Ervebo (Merck), the first FDA-approved vaccine for the prevention of Ebola virus disease, caused by Zaire ebolavirus, in people 18 years of age and older. Ervebo is administered as a single-dose injection and is a live, attenuated vaccine that has been genetically engineered to contain a protein from the Zaire ebolavirus.

Roche, Sarepta enter licensing agreement

February 2020—Roche and Sarepta Therapeutics signed a licensing agreement providing Roche exclusive commercial rights, outside the United States, to SRP-9001 (AAVrh74.MHCK7.micro-dystrophin), Sarepta’s investigational gene therapy for Duchenne muscular dystrophy. Under the terms of the agreement, Sarepta will receive an upfront payment of $750 million in cash and $400 million in equity. In addition, Sarepta is eligible to receive regulatory and sales milestones, and royalties on net sales. Roche and Sarepta will equally share global development expenses. As part of the agreement, Roche also obtains an option to acquire ex-U.S. rights to certain future DMD-specific programs from Sarepta, in exchange for separate milestone and royalty considerations, and cost sharing.

Sample storage, shipping system

February 2020—DriBank Labs announced the availability of its DriBank system for preserving, storing, and shipping laboratory samples. The system preserves small (≤ 3 g or 50 µL) laboratory biological samples at room temperature (20˚C) for up to six months using desiccants contained inside a replaceable and rechargeable cartridge, eliminating the need for chemical fixatives or refrigerants. It accepts samples in a variety of media including microscope slides, microcentrifuge tubes, cell culture dishes, swabs, and others.

NeuMoDx, Sentinel partnership

February 2020—NeuMoDx Molecular and Sentinel Diagnostics announced a partnership to develop diagnostic assays for the NeuMoDx 96 and 288 molecular systems. Sentinel’s real-time PCR assays will be adapted to the NeuMoDx 96 and 288 molecular systems and will incorporate Sentinel’s STAT-NAT technology, which provides the ability to stabilize the activity of a PCR mix, allowing room-temperature storage and transport. The test menu pipeline for the systems will include assays to detect and monitor post-transplant infections, parasitic and hospital-acquired infections, and respiratory infections, and for pharmacogenetics applications.

ArcherDX, Illumina comarketing partnership

February 2020—ArcherDX announced a nonexclusive, multiyear partnership with Illumina intended to broaden access of next-generation-sequencing­–based oncology testing, including companion diagnostics for therapeutic selection, personalized monitoring, and recurrence surveillance IVD tests, upon FDA approval.

 

Horizon Discovery launches new website

February 2020—Horizon Discovery Group went live with a new website and ecommerce system, horizondiscovery.com. Features of the website are improved navigation, including sophisticated gene-based search capabilities and advanced filtering, an intuitive, streamlined purchasing and quotation system, and comprehensive technical support and educational content.

β-hydroxybutyrate prefilled reagent kits

February 2020—Vidan Diagnostics announced the availability of its β-Hydroxybutyrate 21FS prefilled reagent kits, for the quantitative in vitro determination of beta-hydroxybutyrate in serum or plasma, for use with Abbott Architect and Beckman Coulter AU systems.

MARKETPLACE

TRENDING